Latanoprost Teva Sante

Latanoprost, the active ingredient in Latanoprost Teva Sante, is a prostaglandin analog presented as eye drops for ocular use. It lowers intra‑ocular pressure and is indicated for the management of open‑angle glaucoma and ocular hypertension in adult patients. The drug increases uveoscleral outflow of aqueous humor, thereby reducing intra‑ocular pressure.

GNH USA supplies Latanoprost Teva Sante as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with established quality‑assured distribution channels across the EU and other regulated markets.

Latanoprost is a prostaglandin analog used to lower intra‑ocular pressure in glaucoma and ocular hypertension.

Open-angle glaucoma: reduces intra‑ocular pressure to slow disease progression. Ocular hypertension: lowers pressure to prevent conversion to glaucoma. Secondary open-angle glaucoma: helps control pressure in pseudoexfoliative or pigmentary forms.

Latanoprost may cause ocular and systemic reactions.

Common Side Effects: - Eye redness or hyperemia. - Increased eyelash length and density. - Darkening of the iris or peri‑ocular skin. - Mild eye irritation or foreign‑body sensation.

Serious or Rare Side Effects: - Severe allergic reaction (e.g., angio‑edema, anaphylaxis). - Ocular inflammation such as uveitis. - Paradoxical increase in intra‑ocular pressure. - Corneal edema or keratitis. - Vision loss due to optic nerve compromise.

Before initiating therapy, clinicians should evaluate ocular health and baseline intra‑ocular pressure.

Assess baseline IOP: confirm elevated pressure before treatment. Monitor IOP regularly: check pressure after the first week and periodically thereafter. Avoid use with active ocular infection: postpone treatment until infection resolves. Caution in patients with a history of uveitis: monitor for inflammation. Do not wear contact lenses during treatment: lenses may trap medication. Store at room temperature: keep in the original container, protect from light and moisture.

Latanoprost can interact with other ocular or systemic agents.

Major Interactions (Avoid): - Concurrent use with other prostaglandin analogs: risk of additive ocular effects. - Use with non‑steroidal anti‑inflammatory eye drops: may diminish efficacy. - Combination with systemic carbonic anhydrase inhibitors: potential excessive IOP reduction.

Moderate Interactions (Monitor Closely): - Co‑administration with beta‑blocker eye drops: additive pressure‑lowering effect. - Use alongside corticosteroid eye drops: steroids may counteract latanoprost's action. - Combination with ocular anesthetic drops: possible increased ocular irritation.